Rilpivirine, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection.
Tibotec BVBA is developing the diarylpyrimidine rilpivirine, a second-generation non-nucleoside reverse transcriptase inhibitor for the potential treatment of HIV infection. A phase III trial of rilpivirine in HIV-infected, treatment-naive indivuduals is underway and is to be completed by August 2010.
Ripamonti
Diego
D
Malattie Infettive, Ospedali Riuniti di Bergamo, Largo Barozzi 1, 24128 Bergamo, Italy. diego.ripamonti@hotmail.com
Maggiolo
Franco
F
D000818:Animals; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D004347:Drug Interactions; D015658:HIV Infections / Q000188:drug therapy*; D054303:HIV Reverse Transcriptase / Q000037:antagonists & inhibitors; D006801:Humans; D009570:Nitriles / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D010330:Patents as Topic; D011743:Pyrimidines / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D000068696:Rilpivirine
D009570:Nitriles; D011743:Pyrimidines; D018894:Reverse Transcriptase Inhibitors; D054303:HIV Reverse Transcriptase; D000068696:Rilpivirine